Home › RXi Pharmaceuticals Corp (RXII) Downgraded by Zacks Investment Research to "Sell"
 

Keywords :   


RXi Pharmaceuticals Corp (RXII) Downgraded by Zacks Investment Research to "Sell"

2015-12-19 21:28:21| Biotech - Topix.net

According to Zacks, "RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering, developing and commercializing therapies based on its RNAi platform. The Company is developing RXI-109, which is used for the reduction of dermal scarring in planned surgeries, as well as reduces the expression of connective tissue growth factor.

Tags: research sell investment corp

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11UNL commits $5 million to better measure environmental impact of cattle
07.11US cuts interest rates as Trump election raises uncertainty
07.11The Lehigh Short Course Website is Now Open
07.11Carbon Trust Verifies Four BASF Intermediates
07.11Atlantic Tropical Weather Outlook
07.11Eastern North Pacific Tropical Weather Outlook
07.11Producers encouraged to attend Northern Plains Forage Association annual meeting
07.11Labelink acquires International Label & Printing
More »